BARBARA GAYLE DUNCAN
CIK 1353128 · Chief Accounting Officer · last filed 2026-06-23
BARBARA GAYLE DUNCAN is a Chief Accounting Officer who has filed 95 SEC Form 4 insider transactions across 13 companies since 2012. The most recent filing, for AVIR, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$7.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.30M
13
95
-$6.98M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVIR | Director | 92,350 | $4.72 | $436.4K | $0 | 8 | 2026-06-23 |
| HTI | Director | 23,715 | — | — | $0 | 5 | 2026-05-07 |
| OVID | Director | — | $2.22 | — | $0 | 15 | 2026-03-02 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 5 | 2024-06-04 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | 0 | $1.88 | $0 | -$256.2K | 10 | 2023-05-04 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | — | $0.06 | — | $0 | 3 | 2022-07-01 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | 0 | — | — | $0 | 7 | 2020-10-23 |
| ASND | Director | — | $244.51 | — | $0 | 3 | 2019-07-03 |
| GNMX | Director | 59,524 | $29.63 | $1.76M | $75.0K | 4 | 2018-07-18 |
| INVA | Director | 52,318 | $21.02 | $1.10M | $0 | 2 | 2017-04-24 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Chief Accounting Officer | 30,661 | $19.00 | $582.6K | -$6.80M | 25 | 2016-10-05 |
| Aevi Genomic Medicine, LLC (MDGN) Delisted | Director | — | — | — | $0 | 1 | 2016-04-19 |
| Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | Director | — | — | — | $0 | 2 | 2015-08-06 |
Recent Filings
95 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-23 | AVIR | Mixed | +29,600 | $0 | EDGAR |
| 2026-05-07 | HTI | Grant (A) | +3,796 | $0 | EDGAR |
| 2026-03-02 | OVID | Grant (A) | — | $0 | EDGAR |
| 2025-06-24 | AVIR | Mixed | +29,600 | $0 | EDGAR |
| 2025-06-18 | OVID | Grant (A) | — | $0 | EDGAR |
| 2025-05-02 | HTI | Grant (A) | +4,165 | $0 | EDGAR |
| 2024-12-16 | OVID | Grant (A) | — | $0 | EDGAR |
| 2024-06-21 | AVIR | Grant (A) | — | $0 | EDGAR |
| 2024-06-18 | AVIR | Exer (M) | +33,150 | $0 | EDGAR |
| 2024-06-04 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Disp (D) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.